Hangzhou, China, 20 October 2021 — The multi-center clinical trial, ‘Robotic-assisted thoracic, abdominal and pelvic procedures using the Toumai Endoscopic Surgical System, registered by Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot) has completed the first surgery for an enrolled patient.
The surgery, completed at the Sir Run Run Shaw Hospital, affiliated to Zhejiang University School of Medicine, marked the official kick-off of the multi-specialty, multi-center clinical study, which uses the MicroPort® Toumai® Laparoscopic Surgery Robot (Toumai®) in hepato-biliary-gastroenterological surgeries, thoracic surgeries, and gynecology.
Toumai® is an independently-developed robot used for laparoscopic surgeries. The high dexterity of the robotic wrist, realistic 3D views provided by the laparoscopic system, and the intuitive and easy-to-use master-slave remote control offer great benefits in clinical use, as they help simplify surgical operations and shorten the operation time.
Another of MicroPort® MedBot’s flagship products, the DFVision® 3D Electronic Laparoscope, was approved for marketing in June 2021. The Toumai® Laparoscopic Surgery Robot and the Honghu Orthopedic Surgical Robot have also gained access to the NMPA Special Approval Procedure for Innovative Medical Devices, and the registration applications for both products have been filed.
About Shanghai MicroPort MedBot (Group) Co., Ltd.
MicroPort® MedBot is a subsidiary of MicroPort Scientific Corporation (0853.HK, MicroPort®). MicroPort® started its strategic development of medical robots in 2014 and has since been engaged in independent research and development of endoscopic surgical robots. Over the years, MicroPort® MedBot has focused on the development and commercialization of minimally invasive and noninvasive surgical robots, with integrated solutions gradually created for multiple clinical applications on five ‘golden paths’, namely laparoscopy, orthopedics, vascular intervention, natural orifice surgery, and percutaneous puncture.